PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20308917-2 2010 The purpose of this study was to investigate the relative risk of the thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genotypes and TPMT activity for the development of leukopenia in Korean IBD patients during AZA/6-MP treatment. Azathioprine 246-249 inosine triphosphatase Homo sapiens 148-152 21544018-0 2011 Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Azathioprine 42-54 inosine triphosphatase Homo sapiens 67-103 23787247-9 2014 CONCLUSIONS: This study describes the effect of candidate genetic polymorphisms in TPMT, ITPA, and GST-M1 on azathioprine pharmacokinetics in IBD patients, showing, for the first time, relevant effects of GST-M1 genotype on azathioprine metabolites concentration. Azathioprine 109-121 inosine triphosphatase Homo sapiens 89-93 23770441-5 2013 Additionally, certain variations in the human ITPA gene have been linked to adverse reactions to the immunosuppressive prodrugs azathioprine and 6-mercaptopurine and protection against ribavirin-induced hemolytic anemia. Azathioprine 128-140 inosine triphosphatase Homo sapiens 46-50 22673202-4 2012 Here, we report a weak anion exchange high-performance liquid chromatography method to determine ITPase activity in red blood cells and to investigate the relationship with the occurrence of adverse events during azathioprine therapy. Azathioprine 213-225 inosine triphosphatase Homo sapiens 97-103 21961091-0 2011 A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. Azathioprine 165-177 inosine triphosphatase Homo sapiens 37-41 21961091-3 2011 Variants in the Thiopurine S-methyltransferase (TPMT) and Inosine triphosphate pyrophosphatase (ITPA) genes have been associated with AZA toxicity, but also can contribute to the lack of response. Azathioprine 134-137 inosine triphosphatase Homo sapiens 58-94 21961091-3 2011 Variants in the Thiopurine S-methyltransferase (TPMT) and Inosine triphosphate pyrophosphatase (ITPA) genes have been associated with AZA toxicity, but also can contribute to the lack of response. Azathioprine 134-137 inosine triphosphatase Homo sapiens 96-100 21961091-4 2011 The aims of this study were to determine the contribution of TPMT and ITPA variants in the development of AZA-related toxicity and response. Azathioprine 106-109 inosine triphosphatase Homo sapiens 70-74 21961091-5 2011 METHODS: Variants associated with the decrease of enzyme activity in TPMT and ITPA genes were genotyped with the Snapshot system in 232 IBD patients treated with AZA, and correlated with the clinical response and development of adverse drug reactions in a retrospective case-control study. Azathioprine 162-165 inosine triphosphatase Homo sapiens 78-82 21961091-6 2011 RESULTS: Genotypic analysis showed that there is a statistical significance between c.94C > A variant on ITPA gene with non response to AZA treatment (p=0.005) and arthralgia (OR 8.2353; 95%CI 1.752-38.87, p=0.0041), as well as between mutant TPMT alleles and myelosuppression (OR 7.5; 95%CI 1.4456-38.91, p=0.0304). Azathioprine 139-142 inosine triphosphatase Homo sapiens 108-112 21961091-8 2011 Mutant alleles on TPMT and the variant c.94C > A on ITPA gene predict side effects induced by AZA in our population (myelosuppression and arthralgia). Azathioprine 97-100 inosine triphosphatase Homo sapiens 55-59 19682085-2 2010 The aim of this study is to explore in patients with kidney transplantation whether AZA-related side effects can be explained by the inosine triphophate pyrophosphatase (ITPA) or thiopurine S-methyltransferase (TPMT) polymorphisms using both pheno-and genotyping. Azathioprine 84-87 inosine triphosphatase Homo sapiens 133-168 19682085-2 2010 The aim of this study is to explore in patients with kidney transplantation whether AZA-related side effects can be explained by the inosine triphophate pyrophosphatase (ITPA) or thiopurine S-methyltransferase (TPMT) polymorphisms using both pheno-and genotyping. Azathioprine 84-87 inosine triphosphatase Homo sapiens 170-174 19682085-13 2010 Patients with ITPA 94C>A homozygous allele are at high risk to develop AZA-related gastrointestinal toxicity and flu-like symptoms (P < 0.01). Azathioprine 74-77 inosine triphosphatase Homo sapiens 14-18 19682085-14 2010 TPMT wild-type/ITPA variant (homozygote) is closely related to the AZA-induced side effects (P < 0.01). Azathioprine 67-70 inosine triphosphatase Homo sapiens 15-19 17304144-1 2007 Mutations in the inosine triphosphate pyrophosphohydrolase (ITPA) gene causing enzyme deficiency were shown to have pharmacogenetic implications in azathioprine-induced adverse drug reactions. Azathioprine 148-160 inosine triphosphatase Homo sapiens 17-58 20367526-0 2010 Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Azathioprine 142-154 inosine triphosphatase Homo sapiens 0-36 20367526-3 2010 Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Azathioprine 6-9 inosine triphosphatase Homo sapiens 19-55 20367526-3 2010 Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Azathioprine 6-9 inosine triphosphatase Homo sapiens 57-61 20367526-8 2010 In studies using higher doses, ITPA deficiency appears to increase the risk for AZA toxicity. Azathioprine 80-83 inosine triphosphatase Homo sapiens 31-35 20367526-10 2010 It is important to maintain the dose of AZA < 1.5 mg/kg/day for Asian patients with ITPA 94A allele, with careful monitoring of the therapeutic efficacy. Azathioprine 40-43 inosine triphosphatase Homo sapiens 87-91 19129747-0 2009 Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Azathioprine 97-109 inosine triphosphatase Homo sapiens 25-61 19129747-1 2009 We evaluated the relationship between the efficacy of low-dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase (ITPA) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). Azathioprine 63-75 inosine triphosphatase Homo sapiens 98-134 19129747-1 2009 We evaluated the relationship between the efficacy of low-dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase (ITPA) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). Azathioprine 63-75 inosine triphosphatase Homo sapiens 136-140 19129747-1 2009 We evaluated the relationship between the efficacy of low-dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase (ITPA) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). Azathioprine 77-80 inosine triphosphatase Homo sapiens 98-134 19129747-1 2009 We evaluated the relationship between the efficacy of low-dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase (ITPA) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). Azathioprine 77-80 inosine triphosphatase Homo sapiens 136-140 19229528-3 2009 METHODS: The aim of the current study was to evaluate an association between TPMT and ITPA gene polymorphisms and drug intolerance in a cohort of 157 renal transplant recipients treated with azathioprine (AZA). Azathioprine 191-203 inosine triphosphatase Homo sapiens 86-90 19229528-3 2009 METHODS: The aim of the current study was to evaluate an association between TPMT and ITPA gene polymorphisms and drug intolerance in a cohort of 157 renal transplant recipients treated with azathioprine (AZA). Azathioprine 205-208 inosine triphosphatase Homo sapiens 86-90 19214663-3 2009 METHODS: Gene mutations of TPMT and ITPA, the major AZA/6-MP -metabolizing enzymes, were investigated retrospectively in 16 Japanese patients with inflammatory bowel disease (IBD) in whom AZA/6MP treatment induced adverse reactions. Azathioprine 52-56 inosine triphosphatase Homo sapiens 36-40 19214663-3 2009 METHODS: Gene mutations of TPMT and ITPA, the major AZA/6-MP -metabolizing enzymes, were investigated retrospectively in 16 Japanese patients with inflammatory bowel disease (IBD) in whom AZA/6MP treatment induced adverse reactions. Azathioprine 52-55 inosine triphosphatase Homo sapiens 36-40 19214663-8 2009 CONCLUSIONS: It is suggested that the ITPA gene mutation is closely related to the adverse reactions of AZA/6-MP in Japanese patients, and screening for the mutant allele is useful for predicting the most serious adverse reactions, agranulocytosis and acute bone marrow suppression. Azathioprine 104-107 inosine triphosphatase Homo sapiens 38-42 17924837-4 2007 In recent years, evidence has started to accumulate that polymorphisms in the gene encoding ITPase are associated with potentially severe adverse drug reactions towards the thiopurine drugs azathioprine and 6-mercaptopurine. Azathioprine 190-202 inosine triphosphatase Homo sapiens 92-98 19914375-5 2010 Furthermore, the ITPA 94C>A [P32T] variant is associated with an increased risk of adverse drug reactions for patients treated with azathioprine. Azathioprine 135-147 inosine triphosphatase Homo sapiens 17-21 19214663-0 2009 Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. Azathioprine 183-195 inosine triphosphatase Homo sapiens 35-76 19214663-1 2009 BACKGROUND: The main cause of azathioprine (AZA)/6-mercaptopurine (6MP)-induced adverse reactions is a reduction in the activities of the metabolizing enzymes thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA). Azathioprine 30-42 inosine triphosphatase Homo sapiens 201-242 19214663-1 2009 BACKGROUND: The main cause of azathioprine (AZA)/6-mercaptopurine (6MP)-induced adverse reactions is a reduction in the activities of the metabolizing enzymes thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA). Azathioprine 30-42 inosine triphosphatase Homo sapiens 244-248 19214663-1 2009 BACKGROUND: The main cause of azathioprine (AZA)/6-mercaptopurine (6MP)-induced adverse reactions is a reduction in the activities of the metabolizing enzymes thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA). Azathioprine 44-47 inosine triphosphatase Homo sapiens 201-242 19214663-1 2009 BACKGROUND: The main cause of azathioprine (AZA)/6-mercaptopurine (6MP)-induced adverse reactions is a reduction in the activities of the metabolizing enzymes thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA). Azathioprine 44-47 inosine triphosphatase Homo sapiens 244-248 18090994-0 2008 Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Azathioprine 171-183 inosine triphosphatase Homo sapiens 33-69 17113761-3 2007 The ITPA c.94C>A [P32T] sequence variant is associated with an increased risk of adverse drug reactions in patients treated with the thiopurine drug azathioprine. Azathioprine 152-164 inosine triphosphatase Homo sapiens 4-8 17304144-1 2007 Mutations in the inosine triphosphate pyrophosphohydrolase (ITPA) gene causing enzyme deficiency were shown to have pharmacogenetic implications in azathioprine-induced adverse drug reactions. Azathioprine 148-160 inosine triphosphatase Homo sapiens 60-64 29783434-0 2006 Typing TPMT and ITPase to detect azathioprine toxicity. Azathioprine 33-45 inosine triphosphatase Homo sapiens 16-22 16611274-2 2006 The occurrence and type of adverse events to azathioprine may be related to thiopurine S-methyltransferase (TPMT) enzyme activity and to inosine triphophate pyrophosphatase (ITPase) deficiency. Azathioprine 45-57 inosine triphosphatase Homo sapiens 137-172 16611274-2 2006 The occurrence and type of adverse events to azathioprine may be related to thiopurine S-methyltransferase (TPMT) enzyme activity and to inosine triphophate pyrophosphatase (ITPase) deficiency. Azathioprine 45-57 inosine triphosphatase Homo sapiens 174-180 15571265-0 2004 Mutation in the ITPA gene predicts intolerance to azathioprine. Azathioprine 50-62 inosine triphosphatase Homo sapiens 16-20 16431304-0 2006 Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Azathioprine 98-110 inosine triphosphatase Homo sapiens 0-36 16431304-2 2006 Mutations in the thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes have been associated with the occurrence of AZA-related toxicity. Azathioprine 153-156 inosine triphosphatase Homo sapiens 59-95 16431304-2 2006 Mutations in the thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes have been associated with the occurrence of AZA-related toxicity. Azathioprine 153-156 inosine triphosphatase Homo sapiens 97-101 16431304-3 2006 The aim of our study was to determine the relative contribution of ITPA and TPMT mutations to the development of toxicity induced by AZA treatment in IBD patients. Azathioprine 133-136 inosine triphosphatase Homo sapiens 67-71 16431304-9 2006 CONCLUSIONS: ITPA 94C>A and TPMT polymorphisms are associated with AZA-related leukopenia in IBD patients. Azathioprine 70-73 inosine triphosphatase Homo sapiens 13-17 16214825-0 2005 Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Azathioprine 139-151 inosine triphosphatase Homo sapiens 15-37 15564886-1 2004 A 94C>A missense mutation in the ITPA gene which encodes inosine triphosphate pyrophosphatase has been associated with adverse effects from azathioprine, specifically flu-like symptoms, pancreatitis and rash. Azathioprine 143-155 inosine triphosphatase Homo sapiens 36-40 16214825-6 2005 RESULTS: Early drop-out (within 2 weeks) from aza therapy was associated with ITPA 94C > A [P = 0.020; odds ratio (OR), 4.6; 95% confidence interval (95% CI), 1.2-17.4] and low TPMT activity [<10 nmol/(mL erythrocytes . Azathioprine 46-49 inosine triphosphatase Homo sapiens 78-82 16214825-10 2005 For only drop-outs attributable to aza-related side effects (n = 16), there was a significant association with ITPA 94C > A (P = 0.002; OR = 7.8; 95% CI, 2.1-29.1). Azathioprine 35-38 inosine triphosphatase Homo sapiens 111-115 16214825-12 2005 CONCLUSIONS: Patients with ITPA 94C > A mutations or low TPMT activity constitute a pharmacogenetic high-risk group for drop-out from aza therapy. Azathioprine 137-140 inosine triphosphatase Homo sapiens 27-31 16214825-13 2005 ITPA 94C>A appears to be a promising marker indicating predisposition to aza intolerance. Azathioprine 76-79 inosine triphosphatase Homo sapiens 0-4 15571265-2 2004 In 62 patients treated with azathioprine for inflammatory bowel disease, the ITPA 94C>A deficiency-associated allele was significantly associated with adverse drug reactions (OR 4.2, 95% CI 1.6-11.5, p = 0.0034). Azathioprine 28-40 inosine triphosphatase Homo sapiens 77-81 15571265-4 2004 Polymorphism in the ITPA gene thus predicts AZA intolerance. Azathioprine 44-47 inosine triphosphatase Homo sapiens 20-24 15571266-3 2004 A deficiency of ITPase may predict adverse reactions to therapy with the thiopurine drug 6-mercaptopurine and its prodrug azathioprine. Azathioprine 122-134 inosine triphosphatase Homo sapiens 16-22 15167706-0 2004 Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Azathioprine 26-38 inosine triphosphatase Homo sapiens 101-137 15167706-0 2004 Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Azathioprine 26-38 inosine triphosphatase Homo sapiens 139-145 15167706-4 2004 The association between polymorphism in the ITPA gene and adverse drug reactions to AZA therapy was studied in patients treated for inflammatory bowel disease. Azathioprine 84-87 inosine triphosphatase Homo sapiens 44-48 15167706-10 2004 Polymorphism in the ITPA gene predicts AZA intolerance. Azathioprine 39-42 inosine triphosphatase Homo sapiens 20-24 35067667-5 2022 RESULTS: ITPA genotypes and 6-TGN concentration were both associated with the clinical effectiveness of azathioprine (P=0.036 and P=4.6x10-7), with a significant correlation also detected between them (P=0.042). Azathioprine 104-116 inosine triphosphatase Homo sapiens 9-13 15322947-3 2004 Recently, a polymorphism in the inosine triphosphate pyrophosphatase gene (ITPA) has been associated with severe azathioprine toxicity. Azathioprine 113-125 inosine triphosphatase Homo sapiens 75-79 28650902-0 2017 ITPA Activity in Adults and Children Treated With or Without Azathioprine: Relationship Between TPMT Activity, Thiopurine Metabolites, and Co-medications. Azathioprine 61-73 inosine triphosphatase Homo sapiens 0-4 35034963-0 2022 Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis. Azathioprine 63-66 inosine triphosphatase Homo sapiens 15-19 35034963-3 2022 In the present study we performed a systematic review and a meta-analysis, comprising 30 studies and 3582 individuals, to investigate the putative genetic association of two inosine triphosphatase (ITPA) polymorphisms with adverse effects in patients treated with AZA/6-MP. Azathioprine 264-267 inosine triphosphatase Homo sapiens 198-202 28650902-2 2017 The ability of ITPA to modify the thiopurine metabolite levels is currently used to optimize azathioprine (AZA) therapy in relation to thiopurine S-methyltransferase (TPMT) activity, the aim of this study is to investigate ITPA phenotype in a large population and to evaluate the relation between ITPA and TPMT activities and thiopurine metabolites. Azathioprine 93-105 inosine triphosphatase Homo sapiens 15-19 28650902-2 2017 The ability of ITPA to modify the thiopurine metabolite levels is currently used to optimize azathioprine (AZA) therapy in relation to thiopurine S-methyltransferase (TPMT) activity, the aim of this study is to investigate ITPA phenotype in a large population and to evaluate the relation between ITPA and TPMT activities and thiopurine metabolites. Azathioprine 107-110 inosine triphosphatase Homo sapiens 15-19 28650902-2 2017 The ability of ITPA to modify the thiopurine metabolite levels is currently used to optimize azathioprine (AZA) therapy in relation to thiopurine S-methyltransferase (TPMT) activity, the aim of this study is to investigate ITPA phenotype in a large population and to evaluate the relation between ITPA and TPMT activities and thiopurine metabolites. Azathioprine 107-110 inosine triphosphatase Homo sapiens 223-227 28650902-2 2017 The ability of ITPA to modify the thiopurine metabolite levels is currently used to optimize azathioprine (AZA) therapy in relation to thiopurine S-methyltransferase (TPMT) activity, the aim of this study is to investigate ITPA phenotype in a large population and to evaluate the relation between ITPA and TPMT activities and thiopurine metabolites. Azathioprine 107-110 inosine triphosphatase Homo sapiens 223-227 28650902-3 2017 METHODS: ITPA activity was determined in 183 adults and 138 children with or without AZA therapy. Azathioprine 85-88 inosine triphosphatase Homo sapiens 9-13 35159194-3 2022 Recently, thiopurine drug metabolites such as azathioprine have been included in the lists of ITPase substrates. Azathioprine 46-58 inosine triphosphatase Homo sapiens 94-100 30106365-0 2018 Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis : . Azathioprine 26-38 inosine triphosphatase Homo sapiens 115-119 30106365-14 2018 Therefore, we analyzed three AZA metabolism-associated genes for mutations: thiopurine S-methyltransferase (TPMT), inosine triphosphate pyrophosphohydrolase (ITPA), and nucleoside diphosphate linked moiety X-type motif 15 (NUDT15), and we identified ITPA 94C>A mutation. Azathioprine 29-32 inosine triphosphatase Homo sapiens 250-254 30106365-15 2018 This was a rare case of PR3-positive MPA with AZA-induced severe neutropenia that was possibly due to an ITPA gene mutation. Azathioprine 46-49 inosine triphosphatase Homo sapiens 105-109 30106365-16 2018 This case suggests that ITPA gene mutation is related to the adverse reactions of AZA in Japanese patients. Azathioprine 82-85 inosine triphosphatase Homo sapiens 24-28 29327413-0 2018 ITPA Activity in Children Treated by Azathioprine: Relationship to the Occurrence of Adverse Drug Reactions and Inflammatory Response. Azathioprine 37-49 inosine triphosphatase Homo sapiens 0-4 29327413-2 2018 This study investigated (i) the relationships between inosine triphosphate pyrophosphatase (ITPA) activity, an enzyme involved in thiopurine metabolism, and the occurrence of ADRs in children with immunological disease on AZA therapy, and (ii) the relationship between ITPA activity and the inflammatory activity observed in children with IBD. Azathioprine 222-225 inosine triphosphatase Homo sapiens 54-90 29327413-2 2018 This study investigated (i) the relationships between inosine triphosphate pyrophosphatase (ITPA) activity, an enzyme involved in thiopurine metabolism, and the occurrence of ADRs in children with immunological disease on AZA therapy, and (ii) the relationship between ITPA activity and the inflammatory activity observed in children with IBD. Azathioprine 222-225 inosine triphosphatase Homo sapiens 92-96 29327413-9 2018 Therefore, measurement of ITPA activity may help to identify children with IBD predisposed to residual inflammation on AZA therapy. Azathioprine 119-122 inosine triphosphatase Homo sapiens 26-30 26674571-0 2016 TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects. Azathioprine 97-109 inosine triphosphatase Homo sapiens 9-13 27307154-1 2016 Thiopurine methyltransferase (TPMT) and inosine triphosphatase (ITPA) are crucial enzymes involved in the metabolism of thiopurine drugs: azathioprine and 6-mercaptopurine, used in the treatment of leukemia or inflammatory bowel diseases (IBD). Azathioprine 138-150 inosine triphosphatase Homo sapiens 40-62 27307154-1 2016 Thiopurine methyltransferase (TPMT) and inosine triphosphatase (ITPA) are crucial enzymes involved in the metabolism of thiopurine drugs: azathioprine and 6-mercaptopurine, used in the treatment of leukemia or inflammatory bowel diseases (IBD). Azathioprine 138-150 inosine triphosphatase Homo sapiens 64-68 26674571-2 2016 Genetic polymorphisms in thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) were linked with toxicity of azathioprine (AZA). Azathioprine 138-150 inosine triphosphatase Homo sapiens 65-101 26674571-2 2016 Genetic polymorphisms in thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) were linked with toxicity of azathioprine (AZA). Azathioprine 138-150 inosine triphosphatase Homo sapiens 103-107 26674571-2 2016 Genetic polymorphisms in thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) were linked with toxicity of azathioprine (AZA). Azathioprine 152-155 inosine triphosphatase Homo sapiens 65-101 26674571-2 2016 Genetic polymorphisms in thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) were linked with toxicity of azathioprine (AZA). Azathioprine 152-155 inosine triphosphatase Homo sapiens 103-107